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Abstract
Background: We evaluated the in vitro activity of a merochlorin A, a novel compound with a unique carbon skeleton,
against a spectrum of clinically relevant bacterial pathogens and against previously characterized clinical and laboratory
Staphylococcus aureus isolates with resistance to numerous antibiotics.
Methods: Merochlorin A was isolated and purified from a marine-derived actinomycete strain CNH189. Susceptibility testing
for merochlorin A was performed against previously characterized human pathogens using broth microdilution and agar
dilution methods. Cytotoxicity was assayed in tissue culture assays at 24 and 72 hours against human HeLa and mouse
sarcoma L929 cell lines.
Results: The structure of as new antibiotic, merochlorin A, was assigned by comprehensive spectroscopic analysis.
Merochlorin A demonstrated in vitro activity against Gram-positive bacteria, including Clostridium dificile, but not against
Gram negative bacteria. In S. aureus, susceptibility was not affected by ribosomal mutations conferring linezolid resistance,
mutations in dlt or mprF conferring resistance to daptomycin, accessory gene regulator knockout mutations, or the
development of the vancomycin-intermediate resistant phenotype. Merochlorin A demonstrated rapid bactericidal activity
against MRSA. Activity was lost in the presence of 20% serum.
Conclusions: The unique meroterpenoid, merochlorin A demonstrated excellent in vitro activity against S. aureus and C.
dificile and did not show cross-resistance to contemporary antibiotics against Gram positive organisms. The activity was,
however, markedly reduced in 20% human serum. Future directions for this compound may include evaluation for topical
use, coating biomedical devices, or the pursuit of chemically modified derivatives of this compound that retain activity in
the presence of serum.
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Introduction
The constant evolution of bacterial pathogens with resistance to
clinicallyavailable antimicrobial agentsdrives a continuousdemand
for the development of novel antimicrobial agents. In the United
States, Staphylococcus aureus is the leading cause of hospital-associated
and community-associated bacterial infections involving the
bloodstream, skin and soft tissue and other sites, with a the majority
of these pathogens being methicillin-resistant S. aureus (MRSA)
[1,2]. MRSA is endemic in most hospitals, and invasive MRSA
infections have been associated with higher mortality rates than
comparable infections caused by methicillin-susceptible S. aureus
(MSSA), even when adjusting for host factors, with mortality
estimates of about 20% for bacteremia [3]. Currently, the burden of
MRSA infections in the United States is enormous, with almost
100,000 annual cases of invasive infections translating to almost
20,000 deaths, representing a leading cause of infection-related
mortality by a single pathogen [4]. In addition, S. aureus has
historically demonstrated a propensity to develop resistance to
antibiotics quite rapidly after they are introduced clinically,
frequently within 1–2 years [5]. In this setting, the development
ofnovelantimicrobialagentsagainst MRSAcontinuestobeingreat
demand. We have examined the in vitro properties of a novel
meroterpenoid, merochlorin A (Figure 1), against MSSA and
MRSA with a wide range of resistance determinants against most
currently available anti-staphylococcal antibiotics.
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Cultivation and extraction
The actinobacterium (strain CNH-189) was isolated from a near-
shore marine sediment collected off Oceanside, California. It was
identified as a new Streptomyces sp. based on 16S rRNA gene
sequence analysis (accession number HQ214120). The strain was
cultured in sixty 2.8 L Fernbach flasks each containing 1 L of A1
production medium (10 g starch, 4 g yeast extract, 2 g peptone, 1 g
CaCO3,4 0 m gF e 2(SO4)3N4H2O, 100 mg KBr) and shaken at
230 rpm at 27uC. After seven days of cultivation, sterilized XAD-16
resin (20 g/L) was added to adsorb the organic products, and the
culture andresinwereshakenat215 rpmfor2 hours.Theresinwas
filtered through cheesecloth, washed with deionized water, and
eluted with acetone. The acetone was removed under reduced
pressure, and the resulting aqueous layer was extracted with EtOAc
(36500 mL). The EtOAc-soluble fraction was dried in vacuo to yield
4.5 g of crude extract. Note that no specific permits were required
for the collection of ocean floor sediment. The location of sediment
collectionwas not privately-owned or protected territories and there
was no impingement on endangered or protected species.
Purification and Structure Assignment of Merochlorin A
The crude extract was purified by open column chromatogra-
phy on silica gel (25 g), eluted with a step gradient of
dichloromethane and methanol. The dichloromethane/methanol
100:1 fraction contained a mixture of metabolites, which were
purified by reversed-phase HPLC (Phenomenex Luna C-18 (2),
2506100 mm, 2.0 mL/min, 5 mm, 100 A ˚, UV=210 nm) using
an isocratic solvent system from 85% CH3CN to afford
merochlorin A. The structure of merochlorin A was assigned by
comprehensive spectroscopic analysis involving interpretation of
HRMS data (assignment of molecular formula), infrared and UV
spectroscopy (functional groups and chromophore analyses), and
by comprehensive 1D and 2D NMR studies at 500 MHz.
Bacterial strains and in vitro susceptibility testing
Bacterial strains used in this study are described in Tables 1 and
2 [6–15]. Many of these strains have been previously well-
characterized in cited references in these tables. Susceptibility
testing was performed in duplicate using Mueller-Hinton broth
(MHB) and Mueller-Hinton agar (MHA) according to CLSI
methods. Susceptibility of merochlorin A and vancomycin against
MRSA ATCC33591 was also determined in the presence of 20%
activated-pooled human serum (obtained from a pool from healthy
donor serum) and 80% MHB. Using 96-well tissue culture treated
plates (MICROTEST
TM 96, Becton-Dickinson, Franklin Lakes,
NJ), MICs in the presence and absence of serum were determined
through the broth microdilution method. It was noted that in the
presence of serum, the endpoints were difficult to read visually or
via a spectrophotometer. Thus, the color-change indicator,
resazurin (Sigma-Adrich, St. Louis, MO), was used as an endpoint
signal for cell growth as previously shown [16,17]. Resazurin
sodium salt powder was solubilized in sterile water to a final
concentration of 270 mg/40 mL, filtered using a Costar #8160
Spin-XH Centrifuge Tube Filter by centrifugation at 10,000 rpm
for 10 min, and added to each well of the test plate in a final
concentration of 10%. After incubation for 2 hours at 37uC, the
plates were visually evaluated for color change from the blue
indicator to the pink resorufin, a sign of bacterial growth.
Kill curve assays
Overnight cultures of test strains in MHB were diluted 1:1000
in fresh broth (inoculum approximately 5610
5 cfu/ml) containing
merochlorin A at 46 MIC (8–16 mg/L) and incubated with
shaking at 200 RPM at 37uC. Samples at time 0, 4, and 24 hours
were serially diluted 10
0–10
6, and 10 microliters were plated on
TSA plates. Colonies were counted after 20 hours at 37uCt o
calculate surviving cfu/mL.
Post-antibiotic effect (PAE)
An inoculum of approximately 10
7 cfu/mL of MRSA
ATCC33591 was incubated for 1 hour in MHB containing
merochlorin A 2 mg/L (16 MIC) at 37uC with shaking at 200
RPM in a 1.5 mL Eppendorf tube. The bacteria were pelleted by
microcentrifugation, washed twice in PBS, and resuspended in an
equal volume of fresh antibiotic-free MHB. Samples were
obtained at various time points, serially-diluted, and 10 microliters
were plated on TSA plates. Colonies were counted at 20 hours to
calculate cfu/ml over time. The PAE was calculated according to
the Craig and Gudmundsson formula: PAE=T – C. In this
formula, T refers to the time it takes the treated culture to recover
by one-log10 CFU greater then immediately observed after drug
removal (time 0), and C refers to the corresponding recovery time
observed for the untreated control [18].
Population analysis
An inoculum of approximately 5610
7 cfu/mL of MRSA
ATCC33591 was prepared in fresh MHB by transferring several
colonies of overnight growth on MHA plates using sterile
applicators. Ten microliters of serial 10-fold dilutions (10
0–10
7)
were plated in triplicate on MHA plates containing 0, 0.25, 0.5, 1,
2, 4, 8, and 16 mg/L of merochlorin A. Colonies were counted at
20 hours, and surviving bacteria were enumerated for each
concentration.
Cytotoxicity assays
Cytotoxcity was assessed by incubation of HeLa and L929
(American Type Culture Collection (ATCC), Manassas, VA)
mammalian cell lines (2610
4 cells per well) in sterile 96 well tissue
culture-treated plates in the presence of decreasing concentrations
of merochlorin A and incubation at 37uC with 5% CO2 for 24 h.
Figure 1. Chemical structure of merochlorin A.
doi:10.1371/journal.pone.0029439.g001
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(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2Htetrazolium) using
the CellTiter 96H Aqueous non-radioactive cell proliferation assay
according to manufacturer’s instructions (Promega Madison, WI).
This assay measures the reducing potential of viable cells using a
colorimetric reaction, which is quantitated spectrophotometrically
at 490 nm. Cytotoxicity was defined as the concentration which
showed a .50% reduction in absorbance at 490 nm compared to
the merochlorin A-free negative control. Etoposide at 10 mg/L
was used as the positive cytotoxicity control.
Results
Isolation and structure assignment of merochlorin A
The crude extract (4.5 g) was fractionated by open column
chromatography on silica gel (25 g), eluted with a step gradient of
dichloromethane and methanol. The dichloromethane/methanol
100:1 fraction contained a mixture of metabolites, which were
purified by reversed-phase HPLC (Phenomenex Luna C-18 (2),
2506100 mm, 2.0 mL/min, 5 mm, 100 A ˚, UV=210 nm) using
an isocratic solvent system from 85% CH3CN to afford
merochlorin A (1, 12.0 mg), as a pale yellow oil. The molecular
formula for merochlorin A was deduced as C25H29
35ClO4, based
on analysis of HRESIMS data (a pseudomolecular ion peak at m/z
429.1821 [M+H]
+) and on interpretation of
13C NMR data.
Merochlorin A showed strong UV absorptions at 240, 296, and
330 nm, indicating a conjugated aromatic or phenolic functional
group. The IR spectrum showed broad absorptions for multiple
hydroxyl groups (3380 cm
21) and characteristic carbonyl groups
(1704 cm
21). The
1H NMR spectrum of merochlorin A displayed
a pair of meta-coupled aromatic protons [H-4 (dH 6.16), H-6 (dH
6.38)], one olefin proton H-18 (dH 4.92), five methyl singlets H-21
Table 1. In vitro susceptibility against representative strains
of clinically relevant bacterial pathogens for merochlorin A.
Susceptibility Test MIC (mg/L)
Broth Microdilution Agar Dilution
Streptococcus pneumoniae (D39) 2 ND
Streptococcus pyogenes (5448, NZ131) 4 ND
Streptococcus agalactiae (COH1) 4 ND
Bacillus cereus 2N D
Staphylococcus epidermidis (ATCC12228) 4 ND
MRSA (ATCC33591) 2 1
MSSA (ATCC29213) 4 2
Vancomycin-resistant Enterococcus
faecium
21
Vancomycin-resistant Enterococcus
faecalis
11
Clostridium dificile ATCC 700057 0.3 ND
Clostridium dificile (BI) 0.15 ND
Pseudomonas aeruginosa .64 .64
Escherichia coli ATCC25922 .64 .64
Enterobacter cloacae .64 .64
Acinetobacter baumanii .64 .64
Klebsiella pnemoniae .64 .64
doi:10.1371/journal.pone.0029439.t001
Table 2. In vitro susceptibility of merochlorin A against multi-drugresistant S. aureus strains, including those resistant to
contemporary antibiotics.
Strain Number Species Description merochlorin A MIC (mg/L)
SA7817 MRSA Progenitor to 7819 [6] 2
SA7819 MRSA Linezolid resistant, G2756T [6] 2
7819erm MRSA ermC-transformed 7819 [7] 2
SA354 MRSA Bloodstream. Progenitor to 355 [8] 2
SA355 MRSA Linezolid resistant A2500T [8] 2
SA853 MRSA Progenitor of 853b, VAN MIC 1 mg/L (this study) 2
SA853b VISA In vitro selected VISA, VAN MIC 8 mg/L (this study) 2
A5937 MRSA Bloodstream Endocarditis, mecA+, VAN MIC 2 mg/L [9] 2
A5940 VISA Selected in vivo VISA, mecA+, VAN MIC 4 mg/L [9] 2
SA6300 MRSA VAN MIC 2 mg/L, progenitor to SA6298 [9] 2
SA6298 VISA VAN MIC 4 mg/L, selected in vivo [9] 2
SA0616 MSSA Endocarditis, SA701 Progenitor, DAP MIC 0.25 mg/L [10,11] 2
SA0701 MSSA DAP MIC 2 mg/L [10,11] 2
RN6607 MSSA SA502A, tetM, agr group II prototype [12] 4
RN9120 MSSA agr knockout of RN9120 [12] 4
RN9120b MSSA VISA selected in vivo from RN9120, VAN MIC 4 mg/L [12] 4
HIP5836 VISA New Jersey VISA [13] 2
VRSA MI VRSA vanA vancomycin-resistant S. aureus [14] 2
VRSA PA VRSA vanA vancomycin-resistant S. aureus [15] 2
Note: Isolates are grouped together above in cases where they have been isolated from the same patient and/or are the results of manipulations in the laboratory of an
original strain and have been confirmed identical to each other by pulsed-field gel electrophoresis (PFGE).
doi:10.1371/journal.pone.0029439.t002
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(dH 0.81)], and an exchangeable proton 3-OH (dH 11.9). The
13C
NMR and HSQC spectroscopic data revealed two carbonyl, ten
quaternary, four methine, four methyene, and five methyl carbons.
Interpretation of data from 2D NMR experiments allowed three
fragments, a 1,2,3,5 tetrasubstituted benzene moiety, the C-10 side
chain of the molecule, and a propan-2-ylidenecyclopentane
moiety, to be assembled. The first fragment was established from
analysis of a
1H-
1H coupling constant and 2D NMR spectral data.
The meta-coupling of two aromatic protons [H-4 (dH 6.16, d,
J=2.0 Hz), H-6 (dH 6.38, d, J=2.0 Hz)] indicated a 1,2,3,5
tetrasubstituted benzene moiety. A long range HMBC correlation
of the aromatic proton H-4 to carbons C-3 (dC 165.4) and C-5 (dC
166.5) and their carbon chemical shifts suggested the substitution
of the two hydroxyl groups at C-3 and C-5, respectively. The
presence of two hydroxyl groups was confirmed by the
methylation of 5-OH followed by the acetylation of 3-OH. A
chelated hydroxyl proton (dH 11.59, 3-OH) strongly suggested the
presence of a carbonyl group at C-1, which revealed the ketone
group based on the carbon chemical shift of C-1 (dC 193.2). The
second fragment, the C-10 side chain of the molecule, was
established from COSY crosspeaks and HMBC correlations
(Figure 1b). The COSY crosspeaks from the protons H-16
through H-18 [H-16 (dH 1.40, 1.14)- H-17 (dH 2.03, 1.75)- H-18
(dH 4.92)], and the long-range HMBC correlations from an
olefinic proton H-18 to carbons C-19 (dC 131.6), C-20 (dC 18.1),
C-21 (dC 26.1) permitted the assignment of the side chain of the
fragment (C-16 to C-21). The last fragment, a propan-2-
ylidenecyclopentane moiety, was assigned by analysis of COSY
and HMBC spectroscopic data. The COSY crosspeaks between
H-9 and H-15, and long-range HMBC correlations from H-15 to
C-8, C-9, C-13, C-14, and C-23: from two dimethyl singlet H-22
to carbons C-14 and C-23: from H-24 to carbons C-14 and C-23
allowed the construction of the propan-2-ylidenecyclopentane
moiety.
The three fragments were connected by analysis of HMBC
spectroscopic data. The observation of the three bond HMBC
correlations from H-6 to C-2, C-4, and C-8 along with two bond
HMBC correlations from H-6 to C-5 and C-7 permitted the
connection of C-7 to C-8. The connection of C-16 to C-10, of C-
10 to C-11, and of C-10 to C-9 was established by the long-range
HMBC correlations from H-16 to C-9, C-10, C-11, from H-15 to
C-9 and C-10, and from a singlet methyl H-25 to C-9, C-10, C-11,
and C-16. The connection of C-12 with C-8 was determined by
long-range HMBC correlations from H-13 to C-8 and C-12 and
from H-9 to C-8 and C-12. Establishing the connectivity of the
remaining part of the molecule was difficult due to the absence of
any protons correlating with carbons C-1, C-11, and C-12. Thus,
we considered carefully the chemical shifts of C-1 (dC 193.2), C-12
(dC 200.1) and C-11 (dC 91.1): these data led us to place the
remaining chlorine atom at C-11 and to connect C-1 to C-11 and
C-11 to C-12, thus completing the structure assignment of
merochlorin A.
In vitro susceptibility testing using both broth and agar-based
CLSI methods against single strain representatives of clinically-
relevant Gram-positive and Gram-negative bacteria revealed
activity of compound merochlorin A against MSSA, MRSA,
and VRE but no activity against Gram-negatives (Table 1). For
bacteria for which activity was present, agar dilution consistently
gave a single dilution lower MIC than broth microdilution
(Table 1). Of particular interest was the high potency against
Clostridium dificile representative strains, including the contempo-
rary virulent BI strain (also known as the NAP1 or ribotype 027
strain).
Susceptibility testing using various MRSA and MSSA with
resistance to contemporary antibiotics revealed no significant
change in MIC to merochlorin A with the acquisition of resistance
to vancomycin (both intermediate-level VISA and high–level
vanA-mediated VRSA), linezolid, or daptomycin (Table 2). The
MIC of all S. aureus strains tested against merochlorin A was 2–
4 mg/L. Population analysis of ATCC 29213 (MSSA) and ATCC
33591 (MRSA) showed a slightly heterogeneous type of suscep-
tibility for the MSSA and a homogeneous susceptibility for MRSA
(Figure 2).
Examination of an accessory gene regulator (agr) knockout of
MSSA RN9120, derived from strain RN6390b (SA502A) (Table 2)
which has previously demonstrated a proclivity towards develop-
ment of vancomycin intermediate resistant phenotype also did not
show a change in merochlorin A MIC. Agar dilution susceptibility
testing showed one dilution lower MIC than broth-based methods
(data not shown).
Cytotoxicity, defined as a 50% reduction in absorbance at
490 nm measuring the reduced MTS reagent, was noted at
64 mg/L and 2 mg/L in HeLa cells at 24 and 72 hours,
respectively, and at 32 mg/L and 4 mg/L in L929 cells at 24
and 72 hours, respectively.
However, merochlorion A susceptibility testing in MHB
containing 10% and 20% human serum resulted in complete
inactivation of in vitro activity (MIC.64 mg/L) for all strains
tested. The post antibiotic effect against MRSA ATCC33591 was
determined to be 8 and 9 hours at 2 mg/L (16MIC) in 2 separate
experiments.
Killing assays were performed in Mueller-Hinton broth against
linezolid-resistant MRSA and 2 VISA (one mecA+ and one
mecA2). For the VISA strains, fully vancomycin-susceptible
progenitor parent strains were compared in parallel. For all strains
tested, merochlorin A exhibited potent bactericidal activity,
achieving the limit of detection at 24 hours (approximately
10
4 cfu/mL reduction). For both pairs tested, the VISA isolate
showed increased killing at 4 hours compared to the vancomycin
susceptible parent strain (data not shown).
Discussion
We report a novel natural product, merochlorin A, with in vitro
activity against multi-drug resistant Gram-positive organisms,
including C. dificile and MRSA. Merochlorin A (Figure 1) possesses
a new carbon skeleton unrelated to any antibacterial agents
reported to date. This is particularly noteworthy given the paucity
of novel antibiotic classes currently in development for clinical use.
Resistance to commonly-used MRSA agents, including vancomy-
cin (both intermediate and high-level vanA-mediated), linezolid,
and daptomycin did not affect in vitro susceptibility. We evaluated
resistant isolates to contemporary anti-staphylococcal antibiotics
because future agents must be able to counter resistance to these
drugs, which is to be expected in the years ahead with increased
utilization. While resistance to linezolid and daptomycin is rare
among clinical isolates, we anticipate higher resistance rates in the
future. Furthermore, reduced susceptibility across classes that has
been determined between the lipopeptide daptomycin and
intermediate-level glycopeptides resistance in S. aureus, as well as
reduced susceptibility to telavancin mediated by vanA, further
heighten concern about the future of antimicrobial resistance in S.
aureus. This lack of cross-resistance of merochlorin A to
contemporary antibiotics with specific mechanisms of action is
consistent with our preliminary mechanism of action studies
suggesting global inhibition of DNA, RNA, protein, and cell wall
synthesis.
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9 hour post antibiotic effect. Cytotoxicity was favorable in the
24 hour assay but was increased to concentrations close to its
antimicrobial range in the 72 hour assay. Population analyses of a
representative MRSA and MSSA showed a more heterogeneous
susceptibility profile for MSSA and a homogeneous profile for
MRSA.
In light of inhibition by serum, several avenues exist for
merochlorin A. First would be chemical modification of the
compound in order to eliminate serum inactivation while
preserving in vitro activity against MRSA. Our laboratories have
started to develop derivatives based on merochlorin A structure
that are not inhibited by serum and achieve compounds better
suited for systemic use. Other strategies may include development
and formulation as an enterally administered agent against C.
dificile, topical S. aureus decolonization, or the topical therapy of
wound infections, particularly in the setting of rising resistance to
mupirocin in S. aureus [19]. Note that prolonged treatment of
infected devitalized wounds with systemic vancomycin was a
feature of some cases in which patients became colonized with
vancomycin-resistant S. aureus [14,15]. Considerations can also be
made for using this compound to coat biomedical devices such as
central venous catheters that are at risk for becoming colonized
and subsequently infected with resistant Gram-positive pathogens
such as MRSA and S. epidermidis.
In summary, we present merochlorinA, a novel meroterpenoid
compound which may provide a foundation for developing viable
antimicrobial compounds against MRSA and Clostridium dificile
that are unaffected by resistance to currently utilized antimicrobial
classes.
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